Merck & Company Inc (MRK)vsPharming Group NV (PHAR)
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
PHAR
Pharming Group NV
$12.29
-0.08%
HEALTHCARE · Cap: $867.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 17322% more annual revenue ($67.38B vs $386.75M). PHAR leads profitability with a 6.3% profit margin vs 3.6%. PHAR trades at a lower P/E of 38.3x. PHAR earns a higher WallStSmart Score of 55/100 (C).
MRK
Hold44
out of 100
Grade: D
PHAR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Margin of Safety
-32.3%
Fair Value
$11.77
Current Price
$12.29
$0.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Strong operational efficiency at 33.9%
Earnings expanding 74.9% YoY
Reasonable price relative to book value
Revenue surging 20.8% year-over-year
Areas to Watch
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PHAR
The strongest argument for PHAR centers on Operating Margin, EPS Growth, Price/Book. Revenue growth of 20.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PHAR
The primary concerns for PHAR are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while PHAR is a growth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.22 — expect wider price swings.
PHAR is growing revenue faster at 20.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PHAR scores higher overall (55/100 vs 44/100) and 20.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Pharming Group NV
HEALTHCARE · BIOTECHNOLOGY · USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?